<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2378">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04318431</url>
  </required_header>
  <id_info>
    <org_study_id>COVILLE</org_study_id>
    <secondary_id>2020-A00724-35</secondary_id>
    <nct_id>NCT04318431</nct_id>
  </id_info>
  <brief_title>Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children</brief_title>
  <acronym>COVILLE</acronym>
  <official_title>Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children, a Cross-sectional, Prospective, Multicentre, Observational Study in Primary Care.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association Clinique Thérapeutique Infantile du val de Marne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is expected to provide, for the first time, data on Cov2-SARS circulation in&#xD;
      asymptomatic children and children with moderate respiratory symptoms in order to construct&#xD;
      the severity pyramid of this novel pathogen. This information will be essential in the coming&#xD;
      weeks to understand the dynamics of the transmission of this pathogen at the population level&#xD;
      and to highlight the relevance of public health interventions, particularly with regard to&#xD;
      the systematic closure of schools and childcare facilities.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cov2-SARS is an emerging respiratory virus of the coronavirus family responsible for a global&#xD;
      epidemic since November 2019. As of March 10, 2020, it had caused more than 160,000 cases of&#xD;
      corona virus disease (COVID-19), including more than 6,500 deaths worldwide. France is one of&#xD;
      the main epidemic outbreaks with more than 5,000 confirmed cases and the number of diagnosed&#xD;
      patients is increasing every day.&#xD;
&#xD;
      The number of confirmed paediatric cases is relatively low, and the mortality rate in&#xD;
      children is close to zero. This contrast suggests that children are more likely to present&#xD;
      pauci-symptomatic or even asymptomatic forms of the disease, which are therefore undiagnosed&#xD;
      in most cases. Given the rapid spread of this virus, and the fact that indigenous cases&#xD;
      without an obvious chain of transmission now appear to be frequent in France, it is possible&#xD;
      that the pauci-symptomatic or asymptomatic child may play a role in the transmission of the&#xD;
      pathogen and the dynamics of the epidemic, as documented for other respiratory pathogens such&#xD;
      as influenza. Based on this hypothesis, the closure of children's communities has been&#xD;
      organized in France and other highly endemic countries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 14, 2020</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 12, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of asymptomatic children or children with mild respiratory symptoms</measure>
    <time_frame>14 days</time_frame>
    <description>Proportion of asymptomatic children or children with mild respiratory symptoms (mildly-symptomatic children) with a positive SARS-Cov2 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) on rhino pharyngeal swab or/and IgM/IgG positive serology in the Ile-de-France region during an epidemic period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confirmed Cov2-SARS cases by age</measure>
    <time_frame>14 days</time_frame>
    <description>The proportion of confirmed Cov2-SARS cases in mildly-symptomatic and asymptomatic children in different age groups (defined as 6-23 months, 2-4 years, 5-9 years, 10-15 years).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed Cov2-SARS cases by symptoms</measure>
    <time_frame>14 days</time_frame>
    <description>The proportion of confirmed Cov2-SARS cases based on the symptoms presented by the patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>14 days</time_frame>
    <description>The viral load of children with SARS-Cov2 positive Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) depending on the symptoms and the age of the patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other respiratory viruses</measure>
    <time_frame>14 days</time_frame>
    <description>The proportion of co-infection with other respiratory viruses among children with SARS -Cov2 RT-PCR positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sars-Cov2 IgM</measure>
    <time_frame>14 days</time_frame>
    <description>Proportion of patients with Sars-Cov2 IgM +</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sars-Cov2 IgG</measure>
    <time_frame>14 days</time_frame>
    <description>Proportion of patients with Sars-Cov2 IgG +</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">605</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Data collection and rhinopharyngeal swab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>After information, the collection of consent will be carried out. A clinical information sheet will be completed by the investigator in order to collect socio-demographic data, history, clinical symptoms and signs, and complementary examinations performed.&#xD;
During the same consultation, a rhinopharyngeal swab will be taken for the detection of SARS -Cov2 and other respiratory pathogens by PCR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Data collection and rhinopharyngeal swab</intervention_name>
    <description>Testing for SARS -Cov2 and other respiratory pathogens by PCR via nasopharyngeal swabbing and IgM/IgG rapid serology</description>
    <arm_group_label>Data collection and rhinopharyngeal swab</arm_group_label>
    <other_name>IgM/IgG rapid serology</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Asymptomatic children:&#xD;
&#xD;
          -  Age between birth and 15 years&#xD;
&#xD;
          -  Carrying out a visit within the framework defined by the learned societies and&#xD;
             professional organisations representative of paediatrics in France, i.e. :&#xD;
&#xD;
          -  The consultation of the first month and all consultations involving compulsory&#xD;
             vaccinations (2, 4, 5, 11, 12, 16 months).&#xD;
&#xD;
          -  Consultations for acute pathologies, infectious or not.&#xD;
&#xD;
          -  Monitoring of chronic diseases that warrant clinical examination (the majority of&#xD;
             which can be carried out by telemedicine) or in the case of acute exacerbation.&#xD;
&#xD;
          -  In one of the participating outpatient centres&#xD;
&#xD;
          -  During the study period&#xD;
&#xD;
          -  With a clinical examination that does not reveal any progressive infectious pathology&#xD;
&#xD;
        AND Pauci-symptomatic children&#xD;
&#xD;
          -  Age between birth and 15 years,&#xD;
&#xD;
          -  Consultant at one of the participating outpatient centres&#xD;
&#xD;
          -  During the study period&#xD;
&#xD;
          -  And presenting with a mild respiratory infection:&#xD;
&#xD;
          -  Rhinopharyngitis, Acute otitis media, Angina, Bronchitis, etc.&#xD;
&#xD;
          -  Acceptance to participate in the protocol by one of the holders of parental authority&#xD;
&#xD;
          -  Affiliated to a social security&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cabinet du Dr Belaroussi</name>
      <address>
        <city>Boulogne</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Derkx</name>
      <address>
        <city>Champigny-sur-Marne</city>
        <zip>94500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Coicadan</name>
      <address>
        <city>Chennevières-sur-Marne</city>
        <zip>94430</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>14 Av rené Samuel</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Corrard</name>
      <address>
        <city>Combs-la-Ville</city>
        <zip>77380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>10 rue Delambre</name>
      <address>
        <city>Lagny-sur-Marne</city>
        <zip>77400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>157 Avenue du Général Leclerc</name>
      <address>
        <city>Maisons-Alfort</city>
        <zip>94700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>21 Grande Rue Charles de Gaulle</name>
      <address>
        <city>Nogent-sur-Marne</city>
        <zip>94130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Deberdt</name>
      <address>
        <city>Nogent-sur-Marne</city>
        <zip>94130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Wollner</name>
      <address>
        <city>Nogent-sur-Marne</city>
        <zip>94130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4 allée des Norottes</name>
      <address>
        <city>Noisy-le-Grand</city>
        <zip>93160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr D'acremont</name>
      <address>
        <city>Paris</city>
        <zip>75009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>146 Avenue Ledru Rollin</name>
      <address>
        <city>Paris</city>
        <zip>75011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>132 Boulevard du Montparnasse</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Romain</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Turberg-Romain</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>15 Quai Louis Blériot</name>
      <address>
        <city>Paris</city>
        <zip>75016</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Michot</name>
      <address>
        <city>Paris</city>
        <zip>75016</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>24 rue Volta</name>
      <address>
        <city>Puteaux</city>
        <zip>92800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet du Dr Cohen</name>
      <address>
        <city>Saint-Maur-des-Fossés</city>
        <zip>94100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet de Pédiatrie des Docteurs Ravilly et Bessa</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>13 Villa Beauséjour</name>
      <address>
        <city>Vincennes</city>
        <zip>94300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sars-Cov2 rhino-pharyngeal carriage</keyword>
  <keyword>primary care</keyword>
  <keyword>children</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

